NBIX · NASDAQ
Neurocrine Biosciences, Inc.
$148.01 +1.58 (+1.08%)
Company overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NASDAQ
- Market cap
- $15B
- Employees
- 1,800
- Headquarters
- San Diego, CA
- Website
- neurocrine.com
- CEO
- Kyle W. Gano
- Listed
- May 23, 1996
- P/E
- 22.12
- Dividend yield
- 0.00%
Company financials
- Revenue
- $3.1B
- Gross profit
- $3B
- Operating income
- $782M
- EBITDA
- $881M
- Net income
- $669M
- EPS
- $6.71
- Total assets
- $4.9B
- Total debt
- $406M
- Gross margin
- 98.17%
- Net margin
- 21.55%
- Earnings yield
- 4.52%
No geographic segmentation.
Showing FY 2025
NBIX
1D
NASDAQ
O146.44H146.86L145.37C146.43+0.90 (+0.62%)Vol206.08K